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The molecular mechanisms that underlie chromosome 9 open reading frame 72 (C9orf72)-associated
amyotrophic lateral sclerosis and frontotemporal dementia are rapidly emerging. Two potential disease
mechanisms have been postulated – gain or loss of function. We provide an overview of recent advances
that support or oppose gain-of-function and loss-of-function mechanisms.
Recent findings
Since the discovery that a noncoding repeat expansion in C9orf72 was responsible for chromosome 9-
linked amyotrophic lateral sclerosis and frontotemporal dementia in 2011, a plethora of studies have
investigated clinical, pathological and mechanistic aspects of the disease. Loss of function is supported by
reduced levels of C9orf72 in patient brain and functional work, revealing a role of the C9orf72 protein in
endocytic and autophagic pathways and motor function. Gain of function is supported by the presence in
patient brain of both repeat RNA and protein aggregates. Repeat RNA aggregates termed RNA foci, a
hallmark of noncoding repeat expansion diseases, have been shown to sequester proteins involved in RNA
splicing, editing, nuclear export and nucleolar function. Repeat-associated non-ATG dependent translation
gives rise to toxic dipeptide repeat proteins that form inclusions in patient tissue. Antisense oligonucleotides
targeting C9orf72 have shown promise for combating gain-of-function toxicity.
Summary
Rapid progress is being made towards understanding this common genetic cause of amyotrophic lateral
sclerosis and frontotemporal dementia. Overall, the weight of data currently sits in favour of gain of
function as the most important disease mechanism, which has important implications for the development of
effective and targeted therapies.
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cited.INTRODUCTION
A noncoding repeat expansion in C9orf72 is a
common genetic cause of amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar dementia
(FTD) (C9FTD/ALS) [1,2]. Disease may occur
through loss of function of C9orf72, or two distinct
gain-of-function mechanisms: first, the forma-
tion of repeat RNA aggregates, termed RNA
foci, in neuronal nuclei that sequester important
RNA-binding proteins and second, the generation
of toxic, dipeptide repeat (DPR) proteins, due to
the repeat RNA mediating its own translation
(Fig. 1) [3]. In this review, we will cover recent
findings concerning the role of each of these
mechanisms in C9FTD/ALS and their relevance
for developing therapeutics. Key findings relating
to loss or gain of function are summarized in
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NONCODING REPEAT EXPANSION
DISORDERS
Noncoding repeat expansions have been commonly
assigned into two groups: those which cause loss of
function of the protein in which the mutation
resides (fragile X syndrome and Friedreich’s ataxia),thorized reproduction of this article is prohibited.
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CKEY POINTS
 Evidence exists supporting a role for both gain-of-
function and loss-of-function mechanisms in C9FTD/
ALS.
 The weight of evidence currently suggests gain of
function is the primary disease mechanism.
 Loss of function is more likely to modulate the disease
phenotype than be a primary cause of disease.
 Therapeutics that target gain-of-function mechanisms,
such as ASOs, are a promising avenue for therapy.
Nerve, neuro-muscular junction and motor neuron diseasesand those in which a gain-of-function mechanism
has been identified because of repeat RNA species
[myotonic dystrophy, fragile X-associated tremor/
ataxia syndrome (FXTAS), Huntington’s disease-like
2 and spinocerebellar ataxia types 8, 10, 12 and 31].
In the fragile X mental retardation protein (FMRP)
gene, CGG repeat size determines the clinical syn-
drome; expansions of 55–200 repeats result in the
gain-of-function disease FXTAS [32,33], whereasopyright © Lippincott Williams & Wilkins. Unautho
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FIGURE 1. Potential mechanisms of disease in C9FTD/ALS. AP,
GP, glycine-proline; GR, glycine-arginine; PR, proline-arginine.
516 www.co-neurology.comexpansions of more than 200 repeats lead to hyper-
methylation of the FMRP gene, which silences
transcription, leading to a loss of FMRP function
and fragile X syndrome [34]. There is no evidence for
such a bimodalmechanism in C9FTD/ALS, indeed, a
large study found no effect of repeat size on clinical
presentation [35
&
]. The first mechanism attributed
to the gain-of-function noncoding repeat expansion
diseases was toxic functions of the repeat RNA [36].
Recently, a novel mechanism was identified
whereby expanded CAG repeats are translated in
the absence of an ATG initiation codon, termed
repeat-associated non-ATG dependent (RAN) trans-
lation [37]. RAN translation has now been found to
be common to several noncoding repeat expan-
sions, including C9FTD/ALS [38], increasing the
spectrum of potential mechanisms in disease.LOSS OF FUNCTION OF C9ORF72
PROTEIN
The main support for a loss-of-function mechanism
in C9FTD/ALS is numerous reports of decreased
transcript levels of all three C9orf72 mRNA variantsrized reproduction of this article is prohibited.
Gain of function: repeat RNA
Gain of function: DPR protein
Sense RNA foci
Antisense RNA foci
RNA-binding proteins
GA, GP, GR, AP, and PR
protein inclusions
Nuclear and cytoplasmic inclusions
Sequestration of RNA-binding proteins
alanine-proline; DPR, dipeptide repeat; GA, glycine-alanine;
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Table 1. Summary of the key evidence for gain-and loss-of-function mechanisms in C9FTD/ALS
For (þ) or against
() hypothesis Study
Loss-of-function
Reduced mRNA and protein expression
All mRNA isoforms reduced in C9FTD/ALS patient tissue and iPSC neurons R [1,4,5&–7&,8&&]
Reduced C9orf72 protein in C9FTD/ALS patient brain R [9&]
Hypermethylation of C9orf72 promoter reduces transcript levels and
correlates with shorter disease duration
R [10&]
Hypermethylation of C9orf72 promoter reduces transcript levels, increasing
resistance to cellular stress and reducing RNA foci and DPR proteins
– [11&]
Models of loss of protein
Dysregulation of cellular trafficking associated with reduction of C9orf72
protein
R [12–14]
C9orf72 orthologue knockdown in zebrafish has a motor phenotype R [15&]
C9orf72 orthologue knockout in Caenorhabditis elegans has a motor
phenotype
R [16&]
C9orf72 orthologue knockdown in mice has no motor phenotype – [17&&]
Genetics
Lack of coding mutations in C9orf72 protein in C9ALS – [18]
Homozygous C9FTD case not as severe clinically and pathologically as pure
loss-of-function diseases
– [5&]
Gain-of-function: RNA
RNA foci
Sense and antisense foci identified in C9FTD/ALS patient tissue and iPSC
neurons
R [1,6&,8&&,17&&,19&–22&]
Sense foci burden correlates with age-at-onset in C9FTD R [19&]
Sequestration of RNA-binding proteins
ADARB2 – siRNA reduces sense RNA foci in C9ALS iPSC neurons and
exacerbates glutamate-induced toxicity in control iPSC neurons
R [8&&]
hnRNP A1 and pur-alpha – colocalization with sense RNA foci in iPSC motor
neurons
R [22&]
hnRNP A3 – identified in neuronal cytoplasmic and intranuclear inclusions R [23&]
hnRNP H – colocalization with sense RNA foci in patient brain R [24&]
Nucleolin – colocalization with sense RNA foci in patient brain and cells,
indications of nucleolar stress
R [25&]
Pur-alpha – overexpression rescues GGGGCC-dependent degeneration
in Drosophila
R [26&]
Antisense oligonucleotide (ASO) treatment
ASOs reduce sense RNA foci and reverse transcriptome changes and toxicity
in patient fibroblasts and iPSC neurons
R [8&&,17&&,22&]
Gain-of-function: DPR proteins
Inclusion pathology
All DPR proteins found in neuronal cytoplasmic inclusions in C9FTD/ALS
patient brain and iPSC neurons
R [6&,20&,21&,27&&,28&&,29&]
Poly-GA DPR protein inclusions found prior to TDP-43 inclusions in patient
brain
R [30&]
Toxicity
GA DPR protein inclusion distribution does not correlate with
neurodegeneration in C9FTD/ALS patient brain
– [31&]
Poly-GP and poly-PR DPR proteins made from GGGGCC repeats are toxic to
HEK293 cells (other DPR proteins not assessed)
R [21&]
ALS, amyotrophic lateral sclerosis; DPR, dipeptide repeat; FTD, frontotemporal dementia; GA, glycine-alanine; GP, glycine-proline; hnRNP, heterogeneous nuclear
ribonucleoprotein; iPSC, induced pluripotent stem cell; PR, proline-arginine.
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CNerve, neuro-muscular junction and motor neuron diseasesin patient-derived cells and tissue [1,4,5
&
–7
&
,8
&&
].
Reduced levels of C9orf72 transcripts may be due
to hypermethylation of the C9orf72 promoter or
increased histone methylation [7
&
,10
&
,11
&
]. Unex-
pectedly, lower levels of C9orf72 transcripts are also
identified in ALS/FTD cases without C9orf72 repeat
expansion [15
&
], suggesting that loss of C9orf72
could be part of a common pathway affected in
these diseases. Current studies on C9orf72 protein
are limited by a lack of specific antibodies. However,
one study developed a new C9orf72 antibody which
detects a protein of 48 kDa in human cell lines that is
specifically reduced following treatment with siRNA
targeting C9orf72 [9
&
]. This antibody was used to
show reduced C9orf72 protein in frontal cortex, but
not cerebellum, of C9FTD/ALS patient brain com-
pared to ALS caseswithoutC9orf72 repeat expansion
[9
&
], consistent with findings of reduced transcript
levels.
When the mutation was discovered in 2011,
C9orf72 protein was of unknown function. How-
ever, recent studies show that C9orf72 has a high
homology to differentially expressed in normal and
neoplasia proteins [13,14]. This family of proteins
function as guanine nucleotide exchange factors
(GEFs) that activate Rab guanosine 5’-triphosphate
(GTP)ase and therefore regulate membrane traffick-
ing [13,14]. Consistent with this, knockdown of
C9orf72 leads to reduced endocytosis and dysregu-
lated autophagy in human neuroblastoma cells [12].
Impaired autophagy and endolysosomal degra-
dation are implicated in neurodegenerative diseases
[39], thus these data provide a basis for loss of
function playing a role in C9FTD/ALS. However,
better antibodies are urgently needed to definitively
determine the cellular distribution and function
of C9orf72 protein; analysis of innate GEF activity
will also provide important insight into C9orf72
function.
Knockdown of the zebrafish orthologue of
C9orf72 (zC9orf72) with antisense morpholino oli-
gonucleotides leads to axonopathy and motor def-
icits, which can be rescued by expression of human
C9orf72 [15
&
]. Homozygous knockout of the worm
orthologue of C9orf72 (alfa-1) also results in motor
phenotypes [16
&
]. Together, these data suggest that
the loss of C9orf72 protein can lead to motor abnor-
malities, which argues for a role of loss of function in
C9FTD/ALS. Conversely, intracerebroventricular
delivery to adult mice of antisense oligonucleotides
(ASOs) targeting C9orf72 leads to knockdown of
C9orf72 throughout the central nervous system
but does not result in any motor or behavioural
phenotypes [17
&&
]. It is possible that knockdown
of C9orf72 during development has differing effects
to knockdown in adults which could explain theopyright © Lippincott Williams & Wilkins. Unautho
518 www.co-neurology.comdiscrepancy between the models. Also arguing
against a loss-of-functionmechanism, nomutations
have been found in coding regions of the C9orf72
gene [18]. Additionally, a rare homozygous C9orf72
repeat expansion case did not exhibit clinical or
pathological features outside the usual disease spec-
trum as would be expected from reports of homo-
zygous cases in pure loss-of-function diseases [5
&
].
Reduced C9orf72 transcription via cytosine-
phosphate-guanine (CpG) hypermethylation corre-
lated with shorter disease duration suggesting
C9orf72 reduction may play a role in disease [10
&
].
A second study showed C9orf72 promoter CpG
hypermethylation reduced C9orf72 mRNA levels,
but also decreased RNA foci and RAN protein for-
mation in C9FTD/ALS lymphoblasts and brains.
Furthermore, treatment with a demethylating agent
increased the vulnerability of C9FTD/ALS lympho-
blasts to external stressors, suggesting reduction of
C9orf72 levels may be a protective mechanism [11
&
].
On the basis of evidence described above, hap-
loinsufficiency of C9orf72 may cause defects in
endosomal and autophagic processes and motor
function. Therefore, the degree of reduction of
C9orf72 may well modulate the disease phenotype.
However, clinical data suggest that loss of function
is unlikely to be the predominant causative mech-
anism for neurodegeneration in C9FTD/ALS.GAIN OF FUNCTION: REPEAT RNA
RNA gain of function is a common mechanism in
noncoding repeat expansion diseases [40]. The pro-
posed mode of action in these diseases is via seques-
tration of essential RNA-binding proteins into
aggregates of repeat-containing RNA foci, in the
nucleus of affected cells. The most clearly defined
molecular mechanism occurs in myotonic dystro-
phy (DM), a neuromuscular disease caused by CTG
or CCTG repeat expansions in the dystrophia myo-
tonica protein kinase (DMPK) or zinc finger protein
9 (ZNF9) genes (DM type 1 or 2, respectively) [36]. In
DM type 1 or 2, RNA foci containing CUG repeat
RNA sequester the splicing factor muscleblind-like
protein 1, whose loss results in the mis-splicing of a
muscle-specific chloride channel that is directly
responsible for the myotonia observed in patients
[41]. On the basis of this very clear example of
RNA gain of function, great effort has focussed on
investigating this mechanism in C9FTD/ALS. RNA
foci composed of sense and antisense repeat RNA are
present in frontal cortex, hippocampus, cerebel-
lum and spinal cord of C9FTD/ALS patients
[1,6
&
,8
&&
,17
&&
,19
&
–22
&
]. In support of a role in
disease, increased burden of RNA foci in neurons
correlates with lower age-at-onset of disease inrized reproduction of this article is prohibited.
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sense foci in the frontal cortex, the region most
affected in FTD [19
&
]. RNA foci were present in
several types of glial cells (astrocytes, microglia
and oligodendrocytes), but are predominantly a
neuronal phenotype [17
&&
,19
&
,20
&
], which is reflec-
tive of relative expression levels of C9orf72 in these
cell types in mouse [42]. This raises the possibility
that toxicity could arise from non-cell-autonomous
routes. Indeed, astrocytes derived from familial and
sporadic ALS patients, including C9ALS cases, can
exert toxicity to motor neurons [43].
Although RNA foci can be found in the cyto-
plasm, the vast majority are localized in the nucleus
[17
&&
,19
&
]. Several studies have employed bio-
chemical techniques to identify binding partners
of the expanded sense repeat in vitro using differing
methods and sources of protein, reviewed in [44].
Sequestration of some of these proteins into sense
RNA foci has been assessed in patient-derived cells
and tissue (Table 2). Some inconsistency has been
observed between studies, but investigations in
larger cohorts will be needed to clarify whether this
is due to variation between brain regions or patients
or differences due to detection protocols. Splicing
factors constituted a large proportion of identified
RNA-binding proteins. Of these, the splicing factors
heterogeneous nuclear ribonucleoprotein (hnRNP)
A1, hnRNP H and serine/arginine-rich splicing fac-
tor 2 (SRSF2; also known as SC35) are found to be
sequestered into sense RNA foci [22
&
,24
&
,45
&
]. Loss of
function of these proteins would be predicted to
cause downstream changes in splicing in target
mRNAs. All these splicing factors affect splicing of
a wide variety of targets, so a major challenge will be
to determinewhether specific targets are responsibleCopyright © Lippincott Williams & Wilkins. Unau
Table 2. Reported sequestration of RNA-binding proteins into se
RNA-binding protein C9ALS or FTD Patient-derived cell
ADARB2 ALS iPSC-differentiated ne
ALYREF ALS ND
hnRNP A1 ALS and ALS/FTD iPSC-differentiated m
ALS ND
hnRNP Ha ALS ND
ALS Cerebellum and cere
Nucleolin ALS ND
Pur-alpha ALS and ALS/FTD iPSC-differentiated m
SRSF2 (SC35) ALS ND
ALS ND
ADARB2, adenosine deaminase, RNA-specific, B2; ALS, amyotrophic lateral scleros
heterogeneous nuclear ribonucleoprotein; iPSC, induced pluripotent stem cell; ND, n
known as SC35).
aSequestration of hnRNP H into RNA foci was not observed in C9FTD iPSC-neurons
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ation of these targets in C9FTD/ALS patients.
Proteins involved in nuclear mRNA export also
bind to GGGGCC repeats and are sequestered into
foci containing sense RNA transcripts [22
&
,45
&
]. Aly/
REF export factor (ALYREF) functions as an adaptor
for mature RNA, transferring it through the nuclear
RNA export factor 1 pathway to the nuclear pore for
export [46]. Pur-alpha has also been implicated in
nuclear export and trafficking in dendritic RNA
granules for the regulation of local translation
[47,48]. Another RNA-binding protein, hnRNP A3,
which binds GGGGCC repeat RNA in vitro, but does
not colocalize with RNA foci [23
&
], is also proposed
to function in a similar manner [49]. These proteins
may contribute to export of C9orf72 repeat-contain-
ing RNA from the nucleus for C9orf72 and RAN
protein translation or degradation. Sequestration
of these factors into RNA foci may also prevent
export of their other target mRNAs and affect down-
stream cellular functions.
Other proteins found to interact with GGGGCC
repeats were adenosine deaminase, RNA-specific,
B2 (ADARB2) [8
&&
] and nucleolin [25
&
]. ADARB2
colocalizes with sense RNA foci in C9ALS induced
pluripotent stem cell (iPSC)-differentiated motor
neurons and patient motor cortex, leading to sig-
nificant nuclear accumulation of the protein com-
pared with controls. Unexpectedly, knockdown of
ADARB2 results in reduced RNA foci in iPSC motor
neurons, suggesting a role in foci formation or
stabilization. ADARB2 (also known as ADAR3 or
RED2) is a member of the ADAR (adenosine deam-
inase, RNA specific) RNA editing family, but unlike
the other members, lacks editing activity [50].
Decrease in another member of this family, ADAR2,thorized reproduction of this article is prohibited.
nse RNA foci in patient cells and tissue
s Patient tissue Study
urons Motor cortex [8&&]
Cerebellum and spinal cord [45&]
otor neurons [22&]
Cerebellum [45&]
Cerebellum [24&]
bellum and spinal cord [45&]
Motor cortex [25&]
otor neurons [22&]
Cerebellum [24&]
Cerebellum and spinal cord [45&]
is; ALYREF, Aly/REF export factor; FTD, frontotemporal dementia; hnRNP,
ot determined; SRSF2 (SC35), serine/arginine-rich splicing factor 2 (also
[6
&
].
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CNerve, neuro-muscular junction and motor neuron diseasesis thought to underlie excitotoxic loss of motor
neurons in ALS via reduced editing of AMPA recep-
tors subunits [51].
GGGGCC RNA and DNA repeats exhibit stable
G-quadruplex formation in vitro [25
&
,52
&
,53]. These
structures are involved in telomere stability, RNA
splicing, transport and degradation and regulation
of translation [54–56]. A recent study investigated
binding of proteins to GGGGCC RNA hairpins,
GGGGCC G-quadruplexes and antisense GGCCCC
hairpins [25
&
]. The nucleolar protein nucleolin was
shown to have specificity for sense G-quadruplex
structures, and dispersal of nucleolin staining in the
nucleus was observed in C9ALS patient-derived cells
and tissue, with sequestration into sense RNA foci
visible in the motor cortex. Consequences of
impaired nucleolar function were also observed,
including decreased RNA processing and an increase
in the number of P bodies, which are ribonucleo-
protein complexes involved in the degradation of
untranslated RNAs. These changes could be reca-
pitulated when GGGGCC repeats were expressed in
a cell line, implicating nucleolar stress as a gain-of-
function RNA mechanism in C9FTD/ALS.
It is intriguing to speculate whether the hetero-
geneity seen in C9FTD/ALS could be attributed to
differential sequestration of RNA-binding proteins
between brain regions and patients, because of
protein abundance or availability or RNA foci bur-
den. No protein sequestration into antisense RNA
foci has yet been identified, but this could be
important as ASOs targeting sense RNA did not
reverse all transcriptome changes in C9FTD/ALS-
derived fibroblasts [17
&&
]. This suggests antisense
transcripts may also cause transcriptional changes,
potentially through sequestration of RNA-binding
proteins. Repeat RNA may also exert neurotoxic
effects through processes other than RNA foci gener-
ation. In a fly model of myotonic dystrophy and a
cell model of Huntington’s disease, expression of
expanded repeats led to double stranded RNAs that
were processed by the dicer complex into short
siRNAs that exert toxicity by silencing complemen-
tary CAG or CTG repeat-containing transcripts,
respectively [57,58]. It will be interesting to deter-
mine whether this pathway contributes to C9FTD/
ALS. In a similar manner, antisense transcripts may
regulate the levels of sense transcripts, and vice
versa, via antisense-mediated RNAdegradation. This
may explain why sense and antisense RNA foci are
rarely found within the same cell [19
&
,21
&
]. In
Huntington’s disease, antisense transcripts reduce
huntingtin protein expression, partially via dicer
[59]. This mechanism could also contribute to the
reduced C9orf72 transcript levels observed in
C9FTD/ALS patients.opyright © Lippincott Williams & Wilkins. Unautho
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a role of RNA gain of function in C9FTD/ALS are the
abundant sense and antisense RNA foci in patient
tissue that correlate with clinical phenotypes and
can sequester RNA-binding proteins. However, a
clear mechanism definitively linking sequestration
of specific RNA-binding proteins to disease patho-
genesis (as is the case for myotonic dystrophy) is
currently lacking.GAIN OF FUNCTION: DIPEPTIDE REPEAT
PROTEINS
The other novel and potentially toxic species in
C9FTD/ALS are the DPR proteins formed by RAN
translation of the expanded repeat [20
&
,21
&
,27
&&
,
28
&&
,29
&
]. DPR proteins are translated from all
frames of the GGGGCC repeat resulting in poly-
mers of glycine-alanine (GA), glycine-proline (GP)
and glycine-arginine (GR) in the sense frames, and
glycine-proline (GP), alanine-proline (AP) and pro-
line-arginine (PR) in the antisense frames. Although
poly-GP is translated from both sense and antisense
RNA, translationhasbeen found tocontinueafter the
repeat expansion (using antibodies against down-
stream regions), and thus these poly-GP proteins
have different carboxy terminal tails that may
affect their function [21
&
]. All DPR proteins form
widespread neuronal cytoplasmic inclusions in
patient brain [20
&
,21
&
,27
&&
,28
&&
,29
&
] that frequently
colocalize with p62-positive [but not TAR DNA-
binding protein 43 (TDP-43)-positive] inclusions
[28
&&
,29
&
,31
&
,60]. Poly-GP, andpoly-GADPRproteins
additionally display dot-like neuronal intra-
nuclear inclusions [27
&&
,28
&&
,31
&
]. Unlike RNA foci,
DPR inclusions appear to be an exclusively neuronal
phenotype [27
&&
,31
&
,60], possibly reflective of the
clearance ability of mitotic cells.
A detailed pathological analysis of C9FTD/ALS
cases found that TDP-43, but not poly-GApathology,
correlateswithneurodegeneration [31
&
], suggesting a
lack of pathogenicity of poly-GA inclusions. How-
ever, this does not rule out toxicity of soluble GA
polymers or other DPR proteins. Interestingly, rare
C9orf72 cases have been reported with DPR but not
TDP-43 pathology [28
&&
,30
&
]. This suggests DPR
proteins can be toxic without invoking TDP-43 dys-
function.DISSECTION OF GAIN-OF-FUNCTION
MECHANISMS
We have reviewed evidence for gain-of-function and
loss-of-function mechanisms in C9FTD/ALS. How-
ever, it still remains to be determined which species
and pathways are responsible for neurodegenerationrized reproduction of this article is prohibited.
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of sense and antisense RNA foci with DPR, p62 or
TDP-43 protein inclusions is only as frequent as
expected by chance [8
&&
,19
&
–21
&
,45
&
], suggesting
a lack of interdependence between species and dis-
tinct toxicmechanisms.Overexpressionof expanded
GGGGCC repeats (outside the context of theC9orf72
gene) can induce RNA foci formation [20
&
,24
&
] and
DPR protein production [20
&
,21
&
,28
&&
]. Repeats can
also exert toxicity in cell lines [21
&
,24
&
,25
&
], flies [26
&
]
and zebrafish [24
&
], suggesting that gain-of-function
mechanisms are sufficient for neurodegeneration.
Studies have yet to clearly attribute observed toxicity
to repeat RNA or DPR protein species, but one study
showed that increasing expression ofC9orf72 repeats
specifically in the GP (sense) and PR (antisense)
frames can exacerbate toxicity in human HEK293T
cells [21
&
], showing that theseDPRproteins canaffect
cell viability. Impaireddegradationthrough theauto-
phagic system is consistent with the accumulation of
p62 and ubiquitin pathology that is abundant in
C9FTD/ALS cases [61], and the sensitivity of C9FTD
iPSCs specifically to autophagic stressors [6
&
]. How-
ever, it isnot clearwhether theseeffects aredue to loss
of the normal cellular function of C9orf72 or gain of
function due to the accumulation of protein aggre-
gates.THERPAEUTIC TARGETTING OF GAIN-OF-
FUNCTION MECHANISMS
There is considerable excitement about the possib-
ility of ASOs for the treatment of C9FTD/ALS. One
reason for this is that ASOs should ameliorate both
repeat RNA and DPR protein toxicity, and therefore
do not need to wait for a better understanding of the
contribution of each of these mechanisms to disease
pathogenesis. ASOs will not alleviate loss of C9orf72
function, but as discussed above, the weight of
evidence currently suggests gain of function is likely
to be the primary mechanism to address therapeuti-
cally. ASOs targeting sense transcripts reduce sense
RNA foci and ameliorate transcriptome changes and
toxicity in C9FTD/ALS-derived cells [8
&&
,17
&&
,22
&
].
ASOs targeting antisense transcripts may also be
required as it was proposed that antisense RNA-
mediated mechanisms were responsible for the
proportion of transcriptional changes that remain
dysregulated after treatment of patient cells with
ASOs targeting sense repeats [17
&&
]. In addition,
antisense DPR proteins have been shown to be toxic
to cells [21
&
]. Given the precedent of a clinical trial
for ASOs targeting superoxide dismutase 1 (SOD1)
for ALS patients with SOD1 mutations [62], ASO
treatment is currently the most promising prospect
for treating C9FTD/ALS. The development of smallCopyright © Lippincott Williams & Wilkins. Unau
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structure formed by the GGGGCC repeats is
another promising area for therapeutic intervention
[52
&
,63
&
]. Such small molecules would also be pre-
dicted to prevent both repeat RNA and DPR protein
mechanisms, with the potential advantage of
simpler delivery.CONCLUSION
In the 3 years since the discovery of the C9orf72
mutation in ALS and FTD, intense investigations
have begun to unfold the mechanisms at play in
these diseases. Haploinsufficiency of C9orf72 may
cause defects in endosomal and autophagic proc-
esses that lead to dysfunction of the motor system,
but clinical data do not support causation of
disease. Cellular and animal models inform us
that gain-of-function mechanisms from expanded
C9orf72 repeats are sufficient to cause neurodegen-
eration. As has been found in other diseases
classically thought of as either loss-of-function or
gain-of-function diseases, it is likely that both
mechanisms contribute to different aspects of the
heterogeneous phenotypes in these diseases. As the
same C9orf72 mutation appears to result in a spec-
trum of disease phenotypes, differential regulation
of toxic species or the degree of loss of functionmay
play a role in differing disease presentations.
Finally, current evidence suggests gain-of-func-
tion-based therapies such as ASOs hold promise
for C9FTD/ALS.
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